Glucose Tolerance Study

The goal of this clinical trial is to assess whether TRPTI (oleoylethanolamide) can improve glucose tolerance in healthy adults aged 18 years and above with BMI 18.5-29.9 kg/m². The main questions it aims to answer are: * Does TRPTI improve glucose tolerance as measured by glucose area under the curve (AUC) from 0-120 minutes following a glucose load? * Does TRPTI reduce peak glucose response and alter the time to peak glucose concentration? * Are there dose-dependent effects between 150 mg and 300 mg doses of TRPTI? Researchers will compare TRPTI 150 mg, TRPTI 300 mg, and placebo in a crossover design to see if TRPTI improves glucose metabolism and insulin sensitivity compared to placebo. Participants will complete 3 clinic visits (each lasting approximately 4 hours) with a minimum 6-day washout period between visits.

NCT Number	NCT07412730
Lead Sponsor	RDC Clinical Pty Ltd Collaborators: Gencor Pacific Limited, Hong Kong
Conditions	Healthy Volunteers, Glucose Tolerance
Enrollment	19 participants
Start Date	2026-03-11
Primary Completion	2026-04-02 (estimated)
Study Completion	2026-04-02 (estimated)
Updated on ClinicalTrials.gov	2026-04-28